ProfileGDS5678 / 1423344_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 64% 65% 63% 54% 64% 63% 66% 64% 64% 64% 69% 65% 64% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8424664
GSM967853U87-EV human glioblastoma xenograft - Control 23.9418965
GSM967854U87-EV human glioblastoma xenograft - Control 33.7732163
GSM967855U87-EV human glioblastoma xenograft - Control 43.2791454
GSM967856U87-EV human glioblastoma xenograft - Control 53.7911564
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.832263
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.0578766
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.8137364
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.8101464
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8270464
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2296569
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.8549765
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.8292564
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8281364